GlassScriptPhysician profile
Kenneth Kohagen
NPI 1972589935
$6,866.14
in general payments reported to CMS, 2019-2025
25 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $140 · 2021: $295 · 2022: $1,264 · 2023: $1,371 · 2024: $1,755 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,682.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,120.12 | 2019-2025 | |
| Gilead Sciences, INC. | $1,186.35 | 2019-2025 | Livdelzi |
| Boston Scientific Corporation | $826.45 | 2022-2025 | Axios, General - Polypectomy, X-Tack Endoscopic Helix Tacking System |
| Intercept Pharmaceuticals, INC. | $569.60 | 2019-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $286.19 | 2022-2025 | Eohilia, Entyvio |
| Janssen Biotech, INC. | $258.25 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $247.35 | 2022-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $162.65 | 2024 | Iqirvo |
| Erbe USA INC | $142.66 | 2023 | Erbe Apc3 |
| Madrigal Pharmaceuticals | $139.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.36 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $132.00 | 2024-2025 | |
| Ardelyx, INC. | $98.42 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $67.84 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $65.34 | 2024-2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $62.49 | 2021-2022 | |
| Braintree Laboratories, INC. | $59.45 | 2019-2023 | Suflave, Sutab |
| Pfizer INC. | $57.49 | 2019-2024 | |
| Mirum Pharmaceuticals, INC. | $53.70 | 2025 | Livmarli |
| Qol Medical, LLC | $51.30 | 2022-2024 | Sucraid |
| Nestle Healthcare Nutrition INC. | $39.15 | 2022 | |
| Celgene Corporation | $35.94 | 2022-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $31.04 | 2019-2022 | |
| Celltrion USA INC. | $22.85 | 2024 | Vegzelma |
| Micro-Tech Endoscopy USA, INC. | $18.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Kohagen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.